Rezvilutamide

Summary

Rezvilutamide (CHEMBL4650276) is a phase-3 clinical-stage small molecule; indicated across 6 conditions including metastatic prostate carcinoma and breast neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 6 conditions
• Clinical trials: 27
• Chemistry: 479.5 Da · C22H20F3N3O4S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4650276
Name	Rezvilutamide
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	89995232
Molecular formula	C22H20F3N3O4S
Molecular weight	479.5
InChIKey	KRBMOYIWQCZVHA-INIZCTEOSA-N

SMILES: CC1(C(=O)N(C(=S)N1C2=CC=C(C=C2)OC[C@H](CO)O)C3=CC(=C(C=C3)C#N)C(F)(F)F)C

IUPAC name: 4-[3-[4-[(2S)-2,3-dihydroxypropoxy]phenyl]-4,4-dimethyl-5-oxo-2-sulfanylideneimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile

Also known as: Rezvilutamida, Rezvilutamide, Shr3680, REZVILUTAMIDE

Patent coverage: 24 distinct patent families (41 SureChEMBL compound mentions), from 2 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

6 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
metastatic prostate carcinoma	2	MONDO:0004956	EFO:0000196
breast neoplasm	2	MONDO:0021100	MONDO:0007254
tumor of salivary gland	2	MONDO:0021357	EFO:1000384
liver disorder	1	MONDO:0005154	EFO:0001421
triple-negative breast carcinoma	1	MONDO:0005494	EFO:0005537

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 27.

Phase distribution

Phase	Trials
PHASE2	11
PHASE1	6
PHASE3	5
PHASE1/PHASE2	3
Not specified	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05983783	PHASE3	RECRUITING	Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC
NCT07241416	PHASE3	RECRUITING	A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer
NCT07611110	PHASE3	RECRUITING	AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
NCT03520478	PHASE3	UNKNOWN	A Study of SHR3680 in Treating Patients With Hormone Sensitive Prostate Cancer
NCT05009290	PHASE3	TERMINATED	A Trial of SHR3680 in Prostate Cancer Patients Who Are Candidates for Radical Prostatectomy
NCT05406999	PHASE2	RECRUITING	Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer
NCT05753566	PHASE2	RECRUITING	Rezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
NCT06305832	PHASE2	RECRUITING	Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
NCT06348264	PHASE2	RECRUITING	Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma
NCT06387056	PHASE2	RECRUITING	Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)
NCT07230106	PHASE2	RECRUITING	A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer
NCT07407283	PHASE1/PHASE2	RECRUITING	A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer
NCT07490210	PHASE2	NOT_YET_RECRUITING	Rezvilutamide With Radical Prostatectomy and Metastasis-Directed Therapy in Oligometastatic Prostate Cancer
NCT02691975	PHASE1/PHASE2	UNKNOWN	A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer Patients
NCT03741712	PHASE1/PHASE2	TERMINATED	A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC
NCT04102124	PHASE2	TERMINATED	A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPC
NCT04355858	PHASE2	UNKNOWN	Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer
NCT04603833	PHASE2	UNKNOWN	A Study of SHR3680 in Combination With Docetaxel in the Treatment of mCRPC
NCT06134271	PHASE2	UNKNOWN	Rezvilutamide Plus Abiraterone for Metastatic Hormone-sensitive Prostate Cancer
NCT04621669	PHASE1	UNKNOWN	Drug-durg Interaction of SHR3680 With Digoxin, Rosuvastatin Calcium and Metformin Hydrochloride
NCT04631549	PHASE1	UNKNOWN	An Investigational Study of SHR3680 in Participants With Mild to Moderate Liver Impairment and Healthy Participants
NCT04664725	PHASE1	UNKNOWN	Drug-drug Interaction of SHR3680 With Repaglinide and Bupropion
NCT04676035	PHASE1	COMPLETED	The DDI Study Had Been Designed to Investigate the Effect of SHR3680 on the Pharmacokinetics of Midazolam, S-Warfarin and Omeprazole
NCT04903158	PHASE1	UNKNOWN	Relative Bioavailability Study of SHR3680
NCT05607693	PHASE1	UNKNOWN	A SHR3680 QT/QTc Study on Castration-Resistant Prostate Cancer Subjects
NCT07444983	Not specified	NOT_YET_RECRUITING	Rezvilutamide for High-Risk Prostate Cancer After Surgery
NCT07428642	Not specified	COMPLETED	PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).